A New Delivery System for Next-Generation Cell and Gene Therapies

Posted by Maria Whitman on Thu, Apr 25, 2019

Kris Elverum of Turnstone Biologics co-wrote this blog post with Maria Whitman.

The evolution of medicines from small molecules to proteins has greatly advanced patient care, and up until now, our system of therapeutic delivery in the U.S. commercial system has been built with these therapeutics in mind. The next generation of cellular and gene therapies holds tremendous promise for patients, but only if the existing delivery system is revamped. There’s a real risk that most patients won’t benefit from these therapies as stakeholders struggle to find successful business models. In a recent article for Nature’s Gene Therapy, my industry colleague, Kris Elverum, and I take a critical look at the U.S. system and outline what needs to change to make approved cell and gene therapies accessible to patients.


>
Read More

How to Bridge the Medical-Commercial Divide

Posted by Sarah Jarvis on Tue, Apr 09, 2019

John Bienko co-wrote this blog post with Sarah Jarvis. 

Collaboration across field medical teams and commercial sales teams—what’s allowed and what’s not—is a big point of contention in the U.S. pharmaceutical industry today. No wonder, given the spotlight on compliance: since 2008, ZS estimates U.S. pharma companies have been charged $22 billion in fines for improper marketing alone. But there’s more to the collaboration question than just compliance. As we covered in a previous blog, several factors are driving companies to reassess their medical-commercial interaction, including changes in the overall healthcare landscape, increasing ecosystem complexity, and declining commercial sales rep access to physicians. According to ZS’s AccessMonitor™ survey, the percentage of accessible physicians reached by the majority of reps declined from 77% in 2008 to 47% in 2016. In certain specialty areas like oncology, the decline is even steeper: from nearly 77% to 23%. 


>
Read More

Despite the FTC’s Objections, a Mega-Provider Healthcare System Could Be on the Horizon

Posted by Paul Darling on Wed, Aug 03, 2016

The current U.S. healthcare climate seems to produce a significant announcement each week of a hospital merger or acquisition. In fact, more than 100 provider mergers are anticipated for 2016. Amidst all of this M&A activity, the Federal Trade Commission (FTC) has been issuing and winning antitrust challenges for many of the larger provider M&As. Until recently, the FTC has been undefeated in all of the cases that it has challenged.


>
Read More

Adapting to the New Healthcare Ecosystem

Posted by Paul Darling on Wed, Feb 17, 2016

The evolution of U.S. healthcare gained pace and clarity as marked by some key events in 2015.  Specifically, more than 100 announced hospital mergers, three multibillion-dollar payer mergers, the successful defense of federal insurance subsidies in King v. Burwell, and the heated debate on drug prices point to an evolution with a clear direction that has important implications for life sciences companies.


>
Read More